Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients

Conclusions Pegfilgrastim is commonly used for primary prophylaxis during the first cycle of chemotherapy. Hospitalizations for febrile neutropenia occurred most commonly among patients without primary prophylaxis. Pegfilgrastim-associated bone pain occurred in a similar percentage, as reported in randomized controlled trials but less than that reported by survey. Loratadine was the most commonly employed medication to mitigate this adverse effect.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research